Group 1 - The company reported a total revenue of RMB 25.5 million for the six months ending June 30, 2025, with a primary revenue of RMB 13.4 million and other income of RMB 12.1 million [1] - The adjusted loss for the period was RMB 91.8 million, a decrease of RMB 2.4 million compared to the previous year's loss of RMB 94.2 million, attributed to revenue growth and improved operational efficiency [1] - Research and development expenses increased from RMB 82.2 million in the previous year to RMB 88.9 million during the reporting period, primarily due to a rise in share-based payment expenses from RMB 11.7 million to RMB 36.2 million [1] Group 2 - The company's vision is to become a high-potential medical device enterprise with a global perspective, providing innovative products for the treatment of structural heart diseases [2] - The company plans to accelerate the global business layout and progress of the LuX-Valve product series, aiming to become a benchmark in the transcatheter tricuspid valve replacement field [2] - The company aims to enhance operational efficiency, accelerate revenue and profit growth, and continuously innovate to achieve sustainable development of its long-term international strategy [2]
健世科技-B(09877.HK)公布中期业绩 加快推进LuX-Valve系列产品的全球业务布局与进程